Elacestrant Highlights Promise of Oral SERDs in HR+/HER2

Elacestrant Highlights Promise of Oral SERDs in HR+/HER2– Metastatic Breast Cancer

Antoinette R. Tan, MD, MHSc, discusses the promise of oral selective estrogen receptor degraders as they continue to be developed for the treatment of patients with ER-positive, HER2-negative breast cancer, factors that inform treatment decisions following disease progression on a CDK4/6 inhibitor, and the growing role of antibody-drug conjugates across the breast cancer spectrum.

Related Keywords

Arielle Heeke , Neelam Desai , Phasei Program At Levine Cancer Institute , University Of North Carolina , Department Of Medicine , Atrium Health Levine Cancer Institute , Science Summit , Breast Medical Oncology , Phasei Program , Levine Cancer Institute , Carolinas Medical Center Pineville , North Carolina , News , Breast Cancer ,

© 2025 Vimarsana